Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years

Sanofi Pasteur SA0 个研究点目标入组 300 人开始时间: 2014年5月26日最近更新: 2014年6月2日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方
入组人数: 300

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1) Aged 2 to 11 years on the day of inclusion (Scr.)
•2) Subject in good health, based on medical history, physical examination and laboratory parameters (Scr. + V01)
•3) Provision of Assent Form signed by the subject (for subjects = 8 years old) and Informed Consent Form signed by the parents or another legally acceptable representative (and by an independent witness for illiterate parent[s]) (Scr.)
•4) Subject and parents/legally acceptable representative able to attend all scheduled visits and to comply with all trial procedures (Scr. + V01)
•5) For a female subject of child-bearing potential (girls post-menarche), avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to first vaccination, until at least 4 weeks after the last vaccination (Scr.+V01)
•6) Documented receipt of YF vaccine since at least 1 month before the first vaccination (Scr.)
•Are the trial subjects under 18? yes
•Number of subjects for this age range: 300
•F.1.2 Adults (18-64 years) no
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

排除标准

•1) Personal or family history of thymic pathology (thymoma), thymectomy, or myasthenia (Scr.)
•2) For a female subject of child-bearing potential (girls post-menarche), known pregnancy (Scr.)
•3) For a female subject of child-bearing potential (girls post-menarche), known pregnancy or positive pregnancy test in blood sample taken at Scr. (V01)
•4) Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination (Scr.+V01)
•5) Planned participation in another clinical trial during the trial (Scr.)
•6) Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy (Scr.)
•7) Known systemic hypersensitivity to any of the vaccines components or history of a life-threatening reaction to the trial vaccines or to a vaccine containing any of the same substances (Scr.)
•8) Systemic hypersensitivity to YF vaccine or history of a life-threatening reaction to YF vaccine (Scr.)
•9) Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator (Scr.)
•10) Current or past alcohol abuse or drug addiction that may interfere with the subject’s ability to comply with trial procedures (Scr.)
•11) Receipt of any blood or blood-derived products in the past 3 months, that might interfere with the assessment of immune response (Scr.)
•12) Receipt of any vaccine in the 4 weeks preceding the first trial vaccination (Scr. + V01)

研究者

发起方

Sanofi Pasteur SA

相似试验

进行中（未招募）

不适用

Study of Sanofi Pasteur's dengue vaccine in Subjects Aged 2 to 45 Years in MexicoPrevention of symptomatic dengue disease

EUCTR2014-001706-17-Outside-EU/EEASanofi Pasteur SA126

进行中（未招募）

不适用

Study of Sanofi Pasteur's dengue vaccine in Subjects Aged 2 to 45 Years in the PhilippinesPrevention of symptomatic dengue disease

EUCTR2014-001534-29-Outside-EU/EEASanofi Pasteur SA126

已完成

2 期

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy SubjectsDengue Hemorrhagic FeverDengue VirusDengue DiseaseDengue Fever

NCT00875524Sanofi Pasteur, a Sanofi Company180

已完成

2 期

Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 YearsDengue VirusDengue DiseasesDengue FeverDengue Hemorrhagic Fever

NCT00788151Sanofi Pasteur, a Sanofi Company300

进行中（未招募）

不适用

Study of Sanofi Pasteur's Dengue Vaccine in Healthy Children Aged 2 to 11 Years in MalaysiaPrevention of symptomatic dengue disease

EUCTR2014-001717-11-Outside-EU/EEASanofi Pasteur SA250